Zoetis Inc (ZTS)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NYSE
Market Cap: $34.06B
Last updated: Nov 17, 2026 at 11:06 AM ET
Zoetis Inc (ZTS) Financials: Revenue, Profit and Cash Flow
Zoetis reported revenue of $9.47B for the fiscal year ended Dec 31, 2025, up 2.3% from the year before. That year, net income was $2.67B with a net margin of 28.2%, operating cash flow was $2.90B and free cash flow was $2.28B. The quarter ended Sep 30, 2026 had revenue of $2.39B and net income of $591.00M.
Revenue and Margins
The operating margin was 37.5% in the fiscal year ended Dec 2025, the highest of the 10 years shown. Over the 9 years to Dec 2025, revenue grew from $4.89B, a compound annual rate of 7.6%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $9.47B | +2.3% | 71.8% | 37.5% | 28.2% |
| Dec 2024 | $9.26B | +8.3% | 70.6% | 36.1% | 27.0% |
| Dec 2023 | $8.54B | +5.7% | 70.0% | 35.3% | 27.4% |
| Dec 2022 | $8.08B | +3.9% | 69.6% | 36.1% | 26.1% |
| Dec 2021 | $7.78B | +16.5% | 70.4% | 35.5% | 26.2% |
| Dec 2020 | $6.67B | +6.6% | 69.2% | 33.6% | 24.5% |
| Dec 2019 | $6.26B | +7.5% | 68.2% | 31.4% | 24.0% |
| Dec 2018 | $5.83B | +9.8% | 67.2% | 31.1% | 24.4% |
| Dec 2017 | $5.31B | +8.6% | 66.6% | 32.1% | 16.2% |
| Dec 2016 | $4.89B | N/A | 65.9% | 28.5% | 16.8% |
Income Statement
In the fiscal year ended Dec 2025, net income rose 6.8% from the year before. In the quarter ended Sep 2026, net income fell 18.0% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $9.47B | $9.26B | $8.54B | $8.08B | $7.78B | $6.67B | $6.26B | $5.83B | $5.31B | $4.89B |
| Cost of revenue | $2.67B | $2.72B | $2.56B | $2.45B | $2.30B | $2.06B | $1.99B | $1.91B | $1.77B | $1.67B |
| Gross profit | $6.80B | $6.54B | $5.98B | $5.63B | $5.47B | $4.62B | $4.27B | $3.91B | $3.53B | $3.22B |
| Research and development | $698.00M | $686.00M | $614.00M | $539.00M | $508.00M | $463.00M | $457.00M | $432.00M | $382.00M | $376.00M |
| Operating income | $3.55B | $3.34B | $3.02B | $2.92B | $2.76B | $2.24B | $1.97B | $1.81B | $1.71B | $1.39B |
| Net income | $2.67B | $2.50B | $2.34B | $2.11B | $2.03B | $1.64B | $1.50B | $1.42B | $862.00M | $819.00M |
| EBITDA | $4.07B | $3.85B | $3.67B | $3.34B | $3.16B | $2.67B | $2.44B | $2.20B | $1.94B | $1.63B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.39B | $2.47B | $2.26B | $2.39B | $2.42B | $2.47B | $2.20B | $2.32B | $2.39B | $2.36B | $2.19B | $2.21B |
| Gross profit | $1.69B | $1.79B | $1.62B | $1.68B | $1.73B | $1.81B | $1.58B | $1.61B | $1.69B | $1.69B | $1.55B | $1.49B |
| Operating income | $863.00M | $922.00M | $800.00M | $809.00M | $932.00M | $967.00M | $812.00M | $763.00M | $915.00M | $864.00M | $797.00M | $701.00M |
| Net income | $591.00M | $691.00M | $601.00M | $603.00M | $721.00M | $726.00M | $602.00M | $581.00M | $692.00M | $624.00M | $599.00M | $523.00M |
Balance Sheet
As of Dec 2025, total debt of $9.04B exceeded cash and equivalents by $6.59B.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $15.49B | $14.24B | $14.29B | $14.93B | $13.90B | $13.61B | $11.54B | $10.78B | $8.59B | $7.65B |
| Current assets | $6.77B | $5.99B | $6.34B | $7.51B | $6.93B | $6.61B | $4.75B | $4.40B | $4.22B | $3.39B |
| Cash and equivalents | $2.45B | $1.99B | $2.04B | $3.58B | $3.48B | $3.60B | $1.93B | $1.60B | $1.56B | $727.00M |
| Total liabilities | $12.07B | $9.47B | $9.29B | $10.52B | $9.36B | $9.84B | $8.84B | $8.59B | $6.80B | $6.15B |
| Short-term debt | $0 | $1.35B | $3.00M | $1.35B | $0 | $604.00M | $500.00M | $9.00M | $0 | $4.47B |
| Long-term debt | $9.04B | $5.22B | $6.56B | $6.55B | $6.59B | $6.59B | $5.95B | $6.44B | $4.95B | $4.47B |
| Shareholder equity | $3.42B | $4.77B | $5.00B | $4.41B | $4.54B | $3.77B | $2.71B | $2.19B | $1.77B | $1.49B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $15.09B | $15.08B | $15.15B | $15.47B | $15.16B | $14.48B | $14.10B | $14.24B | $14.36B | $14.16B | $14.35B | $14.29B |
| Total liabilities | $11.79B | $11.93B | $11.92B | $12.14B | $9.76B | $9.50B | $9.44B | $9.47B | $9.12B | $9.21B | $9.30B | $9.29B |
| Cash and equivalents | $1.33B | $1.48B | $1.94B | $2.31B | $2.08B | $1.44B | $1.72B | $1.99B | $1.71B | $1.57B | $1.98B | $2.04B |
| Shareholder equity | $3.30B | $3.15B | $3.23B | $3.33B | $5.40B | $4.98B | $4.66B | $4.77B | $5.23B | $4.97B | $5.06B | $5.00B |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 78.6% of operating cash flow. Dividends and share repurchases together came to 180.7% of it.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $2.90B | $2.95B | $2.35B | $1.91B | $2.21B | $2.13B | $1.79B | $1.79B | $1.35B | $713.00M |
| Capital expenditures | $621.00M | $655.00M | $732.00M | $586.00M | $477.00M | $453.00M | $460.00M | $338.00M | $224.00M | $216.00M |
| Free cash flow | $2.28B | $2.30B | $1.62B | $1.33B | $1.74B | $1.67B | $1.33B | $1.45B | $1.12B | $497.00M |
| Dividends paid | $889.00M | $786.00M | $692.00M | $611.00M | $474.00M | $377.00M | $314.00M | $269.00M | $249.00M | $188.00M |
| Share repurchases | $3.23B | $1.86B | $1.09B | $1.59B | $743.00M | $250.00M | $626.00M | $698.00M | $500.00M | $300.00M |
| Investing cash flow | -$748.00M | -$315.00M | -$777.00M | -$883.00M | -$458.00M | -$572.00M | -$504.00M | -$2.26B | -$270.00M | -$214.00M |
| Financing cash flow | -$1.87B | -$2.66B | -$3.11B | -$904.00M | -$1.86B | $123.00M | -$951.00M | $533.00M | -$251.00M | -$903.00M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $824.00M | $655.00M | $401.00M | $893.00M | $936.00M | $605.00M | $515.00M | $905.00M | $951.00M | $502.00M | $595.00M | $897.00M |
| Capital expenditures | $107.00M | $117.00M | $110.00M | $161.00M | $138.00M | $146.00M | $178.00M | $216.00M | $167.00M | $132.00M | $140.00M | $198.00M |
| Free cash flow | $717.00M | $538.00M | $291.00M | $732.00M | $798.00M | $459.00M | $337.00M | $689.00M | $784.00M | $370.00M | $455.00M | $699.00M |
Frequently Asked Questions About ZTS
What is Zoetis' annual revenue?
Zoetis reported revenue of $9.47B for the fiscal year ended Dec 31, 2025.
How fast is Zoetis' revenue growing?
Revenue was up 2.3% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 5.4%.
Is Zoetis profitable?
Yes. Zoetis reported net income of $2.67B for the fiscal year ended Dec 31, 2025, with a net margin of 28.2%.
How much free cash flow does ZTS generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $2.90B minus capital expenditures of $621.00M produced free cash flow of $2.28B.
How much debt does Zoetis have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $9.04B, short-term debt of $0 and cash and equivalents of $2.45B.
ZTS pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts